JP2020503289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503289A5
JP2020503289A5 JP2019531463A JP2019531463A JP2020503289A5 JP 2020503289 A5 JP2020503289 A5 JP 2020503289A5 JP 2019531463 A JP2019531463 A JP 2019531463A JP 2019531463 A JP2019531463 A JP 2019531463A JP 2020503289 A5 JP2020503289 A5 JP 2020503289A5
Authority
JP
Japan
Prior art keywords
conjugate
compound
pharmaceutical composition
group
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066361 external-priority patent/WO2018112176A1/en
Publication of JP2020503289A publication Critical patent/JP2020503289A/ja
Publication of JP2020503289A5 publication Critical patent/JP2020503289A5/ja
Pending legal-status Critical Current

Links

JP2019531463A 2016-12-14 2017-12-14 Hsp90標的化コンジュゲート及びその製剤 Pending JP2020503289A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662434282P 2016-12-14 2016-12-14
US62/434,282 2016-12-14
US201762449260P 2017-01-23 2017-01-23
US62/449,260 2017-01-23
US201762487726P 2017-04-20 2017-04-20
US62/487,726 2017-04-20
PCT/US2017/066361 WO2018112176A1 (en) 2016-12-14 2017-12-14 Hsp90-targeting conjugates and formulations thereof

Publications (2)

Publication Number Publication Date
JP2020503289A JP2020503289A (ja) 2020-01-30
JP2020503289A5 true JP2020503289A5 (enExample) 2021-01-21

Family

ID=62559344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531463A Pending JP2020503289A (ja) 2016-12-14 2017-12-14 Hsp90標的化コンジュゲート及びその製剤

Country Status (7)

Country Link
US (2) US11241500B2 (enExample)
EP (1) EP3554558A4 (enExample)
JP (1) JP2020503289A (enExample)
CN (1) CN110049783A (enExample)
AU (1) AU2017376766A1 (enExample)
CA (1) CA3045041A1 (enExample)
WO (1) WO2018112176A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
US20210000966A1 (en) * 2017-12-14 2021-01-07 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2020056205A1 (en) * 2018-09-14 2020-03-19 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CN109400597B (zh) * 2018-11-08 2020-07-28 西安交通大学 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用
CA3135174A1 (en) * 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN112279863A (zh) * 2019-07-25 2021-01-29 华东师范大学 Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
WO2022047008A1 (en) * 2020-08-26 2022-03-03 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
CN112168825A (zh) * 2020-10-30 2021-01-05 江苏大学 含hsp90抑制剂和parp抑制剂的药物组合物
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
CN115286643B (zh) * 2022-09-02 2023-09-01 南京大学 蛋白质靶向降解化合物及其制备方法和应用
WO2025166213A1 (en) * 2024-02-01 2025-08-07 Fulgent Pharma Llc Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
WO2025214403A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法
WO2025249944A1 (ko) * 2024-05-29 2025-12-04 주식회사 매직불릿테라퓨틱스 열충격 단백질 조절 접합체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
PT2042504E (pt) 2002-09-30 2011-09-07 Bayer Schering Pharma Ag Derivados da azolepirimidina fundida
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ATE514695T1 (de) * 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
SG11201504235UA (en) * 2012-12-28 2015-07-30 Blend Therapeutics Inc Targeted conjugates encapsulated in particles and formulations thereof
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US20190060473A1 (en) * 2016-02-29 2019-02-28 Madrigal Pharmaceuticals, Inc. Hsp90 inhibitor drug conjugates

Similar Documents

Publication Publication Date Title
JP2020503289A5 (enExample)
Sanches et al. Is prodrug design an approach to increase water solubility?
ES2622471T3 (es) Compuestos y procedimientos para la administración de análogos de prostaciclina
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
ES2637266T3 (es) Derivados fumarato de ácido graso y sus usos
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US20100010059A1 (en) Anticancer oral formulation
JP2013519653A5 (enExample)
CN104768931A (zh) 化合物及其治疗用途
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
JP2019104739A (ja) Sn−38の徐放性コンジュゲート
CN107343958A (zh) 多巴胺激动剂的胃肠外制剂
JP2022539523A (ja) カンナビノイド抱合分子
US10759803B2 (en) Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
JP2014532727A (ja) 疎水性カンプトテシン誘導体の医薬組成物
Zhan et al. Discovery of 6-(difluoro (6-(4-fluorophenyl)-[1, 2, 4] triazolo [4, 3-b][1, 2, 4] triazin-3-yl) methyl) quinoline as a highly potent and selective c-Met inhibitor
US20050130882A1 (en) Combination therapy including 9-nitro-20(S)-camptothecin
US20220040194A1 (en) Use of olanzapine for treatment of parp-inhibitor-induced nausea
Yan et al. Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
CN101437505A (zh) 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途
TWI638825B (zh) 抑制癌症及病毒之化合物
CN112996533B (zh) 基于聚合物的大分子前药
Zheng et al. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs
Wang et al. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue
KR20230117574A (ko) 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합